Document 2792
 DOCN  M94A2792
 TI    Prevention of severe neutropenia in AIDS patients with intermittent,
       low-dose G-CSF (filgrastim).
 DT    9412
 AU    Balbiano R; Degioanni M; Valle M; Crivelli P; Bordino C; Mastinu A;
       Biglino A; Department of Infectious Diseases, General Hospital, Asti,
       Italy.
 SO    Int Conf AIDS. 1994 Aug 7-12;10(1):223 (abstract no. PB0323). Unique
       Identifier : AIDSLINE ICA10/94369783
 AB    OBJECTIVE: to evaluate the efficacy of an intermittent, low dosage of
       G-CSF in maintaining neutrophil count above 1000/microliters in AIDS
       patients at risk of developing severe neutropenia (< 500 microliters).
       METHODS: Ten consecutive patients with AIDS and neutrophil counts > 500
       < 1000/microliters, treated with zidovudine 500 mg/day, plus either
       cotrimoxazole or gancyclovir as secondary prophylaxis, received 5
       micrograms/kg/week of G-CSF subcutaneously in two divided doses for 6
       months. Neutrophils/microliters were evaluated biweekly, CD4+
       cells/microliter monthly, HIV p24 at 0 and 6 months. Presence of
       pyogenic/opportunistic infections during follow-up (F.U.) was
       investigated weekly. RESULTS are reported in the table. TABULAR DATA,
       SEE ABSTRACT VOLUME. CONCLUSIONS: Even at low, intermittent dosage
       filgrastim seems to prevent severe neutropenia and its pyogenic
       complications in leukopenic patients with AIDS taking potentially
       myelotoxic drugs.
 DE    Acquired Immunodeficiency Syndrome/BLOOD/*COMPLICATIONS/DRUG  THERAPY
       AIDS-Related Opportunistic Infections/PREVENTION & CONTROL  Biological
       Response Modifiers/*THERAPEUTIC USE  Drug Evaluation  Drug Therapy,
       Combination  Female  Ganciclovir/ADVERSE EFFECTS/THERAPEUTIC USE
       Granulocyte Colony-Stimulating Factor/*THERAPEUTIC USE  Human  HIV Core
       Protein p24/BLOOD  Leukocyte Count  Male  Neutropenia/CHEMICALLY
       INDUCED/*PREVENTION & CONTROL/THERAPY  Recombinant Proteins/THERAPEUTIC
       USE  Treatment Outcome  Trimethoprim-Sulfamethoxazole
       Combination/THERAPEUTIC USE  T4 Lymphocytes  Zidovudine/ADVERSE
       EFFECTS/THERAPEUTIC USE  MEETING ABSTRACT

       SOURCE: National Library of Medicine.  NOTICE: This material may be
       protected by Copyright Law (Title 17, U.S.Code).